<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;European guidelines on cardiovascular disease prevention in clinical practice (version 2012).&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012 Jul;33(13):1635-701. [568 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22555213&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A, European Society of Cardiology (ESC), European Association for Cardiovascular Prevention and Rehabilitation (EACPR), Council on Cardiovascular Nursing, European Association for Study of Diabetes (EASD), International Diabetes Federation Europe (IDF-Europe), European Stroke Initiative (EUSI), International Society of Behavioural Medicine (ISBM), European Society of Hypertension (ESH), WONCA Europe (European Society of General Practice/Family Medicine), European Heart Network (EHN), European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies [trunc]. Eur J Cardiovasc Prev Rehabil 2007 Sep;(14 Suppl 2):S1-113.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Diagnostic ultrasound of heart  (88.72); Dysmetabolic syndrome X  (277.7); Electrocardiogram  (89.52); End stage renal disease  (585.6); General physical examination  (89.7); Hypoglycemia, unspecified  (251.2); Loss of weight  (783.21); Peripheral vascular disease, unspecified  (443.9); Unspecified intracranial hemorrhage  (432.9); Unspecified sleep apnea  (780.57)"/><FieldValue Value="MSH: Adrenergic beta-Antagonists ; Alcohol Drinking ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Ankle Brachial Index ; Anticoagulants ; Antihypertensive Agents ; Aspirin ; Auscultation ; Biological Markers ; Blood Chemical Analysis ; Blood Pressure Determination ; Body Mass Index ; Calcium Channel Blockers ; Cardiovascular Diseases ; Clofibric Acid ; Cognitive Therapy ; Coronary Disease ; Diabetes Mellitus, Type 2 ; Diet ; Diet, Sodium-Restricted ; Dipyridamole ; Diuretics ; Drug Therapy, Combination ; Echocardiography ; Electrocardiography ; Erectile Dysfunction ; Exercise ; Exercise Test ; Genetic Testing ; Goals ; Health Services for the Aged ; Heart Auscultation ; Heart Rate ; Hemoglobin A, Glycosylated ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypoglycemia ; Hypoglycemic Agents ; Intracranial Hemorrhages ; Kidney Failure, Chronic ; Life Style ; Magnetic Resonance Imaging ; Medical History Taking ; Medication Adherence ; Metabolic Syndrome X ; Metformin ; Motor Activity ; Niacin ; Nursing Care ; Peripheral Vascular Diseases ; Physical Examination ; Platelet Aggregation Inhibitors ; Preventive Health Services ; Primary Health Care ; Purinergic P2Y Receptor Antagonists ; Risk Assessment ; Risk Factors ; Risk Reduction Behavior ; Self-Help Groups ; Sleep Apnea Syndromes ; Smoking Cessation ; Stroke ; Ticlopidine ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed ; Weight Gain ; Weight Loss ; Women's Health Services "/><FieldValue Value="MTH: Adherence To Medication Regime ; Adrenergic beta-Antagonists ; Alcohol consumption ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Ankle brachial pressure index (observable entity) ; Ankle brachial pressure index (procedure) ; Anticoagulants ; Antihypertensive Agents ; Antilipemic agent ; Aspirin ; Auscultation ; Biological Markers ; Blood Chemical Analysis ; Blood glucose measurement ; Blood pressure determination ; Body mass index procedure ; Body Weight decreased ; C-reactive protein measurement ; Calcium Channel Blockers ; Cardiovascular Diseases ; Care given by nurses ; Cerebrovascular accident ; Cessation of smoking ; Cognitive Therapy ; Combination Drug Therapy ; Computed Tomography Scanning Systems ; CORONARY ARTERIOSCLEROSIS ; Coronary heart disease ; Creatine measurement ; Diabetes Mellitus, Non-Insulin-Dependent ; Diet ; Dipyridamole ; Echocardiography ; Electrocardiography ; Erectile dysfunction ; Exercise ; Exercise stress test ; Fibrinogen assay ; Genetic screening method ; Glucohemoglobin measurement ; Glucose measurement, urine ; Glycosylated hemoglobin A ; heart rate ; High density lipoprotein measurement ; Homocystine measurement ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypoglycemia ; Kidney Failure, Chronic ; Life Style ; Lipoprotein (a) measurement ; Low density lipoprotein cholesterol measurement ; Low sodium diet ; Magnetic Resonance Imaging ; Metabolic Syndrome X ; Niacin ; objective (goal) ; Pedal pulse ; Peripheral Vascular Diseases ; Physical activity ; physical examination ; Plasma Glucose Measurement ; Platelet Aggregation Inhibitors ; Primary Health Care ; Psychosocial assessment (procedure) ; Risk Assessment ; risk factors ; Serum cholesterol measurement ; Sleep Apnea Syndromes ; Support Groups ; Treadmill, device ; Urine protein test ; Weight Gain ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: acetylsalicyclic acid ; biological markers ; computed tomography ; dipyridamole ; hypoglycemia ; magnetic resonance imaging ; niacin "/><FieldValue Value="SNOMEDCT_US: Alcohol intake  (160573003); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Ankle brachial pressure index  (401221002); Ankle brachial pressure index  (446841001); Anticoagulant  (372862008); Anticoagulant  (81839001); Antilipemic agent  (373267003); Antilipemic agent  (57952007); Aspirin  (387458008); Aspirin  (7947003); Assessment for risk of cardiovascular disease  (441829007); Auscultation  (129436005); Auscultation  (37931006); Auscultation of heart  (449263002); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Blood chemistry  (166312007); Blood pressure taking  (46973005); C-reactive protein measurement  (55235003); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Cerebral artery occlusion  (20059004); Cerebrovascular accident  (230690007); Clinical chemistry analyzer  (11987000); Clopidogrel  (108979001); Clopidogrel  (386952008); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Computerized axial tomography  (77477000); Coronary arteriosclerosis  (53741008); Coronary heart disease risk  (315290008); Creatine measurement  (104612006); Diet good  (226234005); Diet good  (310500000); Dietary finding  (41829006); Dipyridamole  (387371005); Dipyridamole  (66859009); Disorder of cardiovascular system  (49601007); Diuretic  (30492008); Diuretic  (372695000); Echocardiography  (40701008); Education about alcohol consumption  (281078001); Electrocardiographic procedure  (29303009); End stage renal disease  (46177005); End stage renal disease  (90688005); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Exercise tolerance test  (165079009); Fasting lipid profile  (252150008); Fibrinogen assay  (250346004); Fibrinogen assay  (90744006); Foot pulse, function  (422121001); Genetic test  (405824009); Glucohemoglobin measurement  (40402000); Glucose measurement, blood  (33747003); Glucose measurement, plasma  (72191006); Glucose measurement, urine  (30994003); Glycosylated hemoglobin A  (33601001); Goal  (410518001); Heart rate  (364075005); High density lipoprotein measurement  (17888004); High density lipoprotein measurement  (28036006); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Homocystine measurement  (104734004); Hypoglycemia  (237630007); Hypoglycemia  (271327008); Hypoglycemia  (302866003); Hypoglycemic agent  (312064005); Hypoglycemic agent  (373299009); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Imaging of carotid arteries  (58920005); Impotence  (397803000); Intracranial hemorrhage  (1386000); Life style  (134436002); Life style  (60134006); Lipoprotein (a) measurement  (121806006); Low density lipoprotein cholesterol measurement  (113079009); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Medication compliance  (182884001); Medication compliance  (418633004); Metabolic syndrome X  (237602007); Metformin  (109081006); Metformin  (372567009); Niacin  (273943001); Niacin  (63639004); Peripheral vascular disease  (400047006); Physical activity  (48761009); Physical activity  (68130003); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Primary prevention of cardiovascular disease  (440358008); Psychosocial analysis assessment  (371585000); Psychosocial analysis assessment  (408920002); Risk assessment  (225338004); Risk factor  (80943009); Sleep apnea  (73430006); Support groups  (224879000); Ticlopidine  (108971003); Ticlopidine  (386950000); Treadmill  (1211003); Type 2 diabetes mellitus  (44054006); Under care of cardiologist  (305472002); Urine protein test  (167271000); Urine protein test  (171247004); Urine protein test  (57378007); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005); Weight gain  (161831008); Weight gain  (262286000); Weight gain  (8943002); Women's health service  (2651000175101)"/><FieldValue Value="SPN: SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Analyzers, Laboratory, Clinical Chemistry  (15-551); Exercisers, Aerobic, Treadmill  (14-141); Physiologic Monitor Modules, Electrocardiography  (20-771); Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Ultrasonic, Cardiac  (17-422)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse:&lt;/strong&gt; This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm437415.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;March 9, 2015 &amp;ndash; Chantix and Varenicline&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol. Interactions between alcohol and Chantix have resulted in some patients experiencing increased intoxicating effects of alcohol, sometimes associated with aggressive behavior and/or amnesia. In addition, rare accounts of seizures in patients treated with Chantix have been reported. FDA has approved changes to the Chantix label to warn about these risks. Refer to the Drug Safety Communication for a detailed data summary. &lt;/li&gt;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Cardiovascular disease, including coronary heart disease, stroke, peripheral artery disease and their complications&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nutrition" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To give an update of the present knowledge in preventive cardiology for physicians and other health workers&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;European patients with established cardiovascular disease (CVD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asymptomatic individuals in Europe who are at increased risk of CVD mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;First-degree relatives of Europeans with premature CVD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other individuals encountered in routine clinical practice &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Risk Assessment/Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk estimation using the Systematic Coronary Risk Evaluation (SCORE) risk prediction system, considering age, gender, smoker status, systolic blood pressure, and cholesterol level &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing (not recommended) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment in women and older people &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of psychosocial risk factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of inflammatory and thrombotic biomarkers (high-sensitivity C-reactive protein [CRP], homocysteine, fibrinogen, lipoprotein-associated phospholipase 2 [LpPLA2]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Imaging studies, including carotid artery scanning, measurement of ankle-brachial index, computed tomography for coronary calcium, exercise electrocardiography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment and stratification in patients with chronic kidney disease, obstructive sleep apnoea, and erectile dysfunction &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Use of cognitive/behavioural methods to support adoption of a healthy lifestyle &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle interventions&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Smoking cessation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Healthy diet &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Increased physical activity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of psychosocial factors &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Weight reduction &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of hypertension&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lifestyle measures &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antihypertensive drug treatment (diuretics, angiotensin-converting enzyme [ACE] inhibitors, calcium antagonists, angiotensin receptor antagonists, and beta-blockers) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Risk stratification using SCORE &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antiplatelet therapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of type 2 diabetes&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Targeted glycated haemoglobin (HbA&lt;sub&gt;1c&lt;/sub&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Statins &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Avoiding hypoglycaemia and excessive weight gain &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Metformin as first-line therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Establishing targets for blood pressure and low-density lipoprotein (LDL)-cholesterol levels &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of hyperlipidaemia&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Establishing target levels of total plasma cholesterol and LDL-cholesterol &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Intervention strategies based on total cardiovascular risk and LDL-cholesterol level &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Statins &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Lifestyle interventions &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antithrombotic therapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Dual antiplatelet therapy with a P2Y12 inhibitor added to aspirin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Clopidogrel &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dipyridamole plus aspirin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Aspirin alone &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interventions to ensure medication adherence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular disease prevention programmes&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Nurse-coordinated care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Role of physician in general practice &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Role of cardiologist &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Primary care-based self-help programmes &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hospital-based programmes &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Non-governmental organization programmes &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Cardiovascular disease morbidity and mortality&lt;/li&gt;&#xA;    &lt;li&gt;All-cause mortality&lt;/li&gt;&#xA;    &lt;li&gt;Survival rate &lt;/li&gt;&#xA;    &lt;li&gt;Quality of life&lt;/li&gt;&#xA;    &lt;li&gt;Risk of myocardial infarction, stroke, and coronary heart disease&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;PubMed, Medline, Scopus, EMBASE, and Cochrane databases were searched over the 10 previous years. The following specific search terms were used: cardiovascular disease, prevention, risk assessment, risk management, smoking, nutrition, physical activity, psychosocial factors.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence (European Society of Cardiology [ESC] System)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from multiple randomized clinical trials or meta-analyses.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from a single randomized clinical trial or large non-randomized studies.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus of opinion of the experts and/or small studies, retrospective studies, registries.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence (Grading of Recommendations Assessment, Development, and Evaluation [GRADE] System [adapted])&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;High quality evidence&lt;/strong&gt; - Further research is unlikely to change confidence in the estimate of effect.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Moderate, Low, and Very Low quality evidence&lt;/strong&gt; - Any estimate of effect is very uncertain.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation Methods&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The present guidelines follow the quality criteria for development of guidelines, which can be found at the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/development.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Experts from the nine organizations performed a comprehensive review and a critical evaluation of diagnostic and therapeutic procedures, including assessment of the risk&amp;ndash;benefit ratio. The level of evidence and the strength of recommendation of particular treatment options were weighed and graded according to the ESC recommendations (see the &quot;Rating Scheme for the Strength of the Evidence&quot; and the &quot;Rating Scheme for the Strength of the Recommendations&quot; fields).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Combining Evaluation Methods&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An important novelty in reviewing quality of evidence and making recommendations is the use of both the ESC-recommended method of evaluation and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) rating system. In contrast to the 2007 guidelines, the Joint Task Force (JTF) has chosen to provide guidance with both systems so that readers acquainted with the former method and those preferring GRADE will find their individually adapted but still congruent guidance in the combined recommendation tables.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The JTF introduced GRADE as it uses a transparent and rigorous process to assess the quality of evidence in terms of whether further research would or would not change confidence in the estimate of intervention effects or diagnostic accuracy. Specific quality indicators are: study limitations, inconsistency of findings, indirectness of evidence, imprecision, and publication bias (see Table 3 in the original guideline document). These are applied to each outcome of critical importance for decision-making in the judgement of the guideline group (e.g., reduction in clinical events is usually critical; changes in biochemical values are not usually critical). Judgements are then made on these indicators to rate evidence quality from &lt;em&gt;high&lt;/em&gt; (i.e., further research is unlikely to change confidence in the estimate of effect), to &lt;em&gt;moderate, low, &lt;/em&gt;and&lt;em&gt; very low&lt;/em&gt; (i.e., any estimate of effect is very uncertain). This judgement is made on quality of evidence for the critical outcomes and not those that are not critical for decision-making.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The value of this new approach is that systematic review or randomized control trial (RCT) evidence that is biased, inconsistent, or imprecise may be downgraded from high- to moderate- or low-quality evidence. Similarly, observational data from cohort or case&amp;ndash;control studies may be upgraded from moderate or low (as is typical in the old levels-of-evidence approach) to high if bias is unlikely, and findings are consistent and precise. This is very helpful in assessing evidence for cardiovascular disease (CVD) prevention where RCTs of health behaviours are difficult to conduct and may be misleading.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The present update from the fifth Joint Task Force (JTF) reflects the consensus on the broader aspects of cardiovascular disease (CVD) prevention from the nine participating organizations (European Society of Cardiology [ESC], European Atherosclerosis Society, European Society of Hypertension, European Society of General Practice/Family Medicine, European Heart Network [EHN], International Society of Behavioural Medicine, European Association for the Study of Diabetes, International Diabetes Federation Europe, and European Stroke Organisation). For more detailed guidance, reference is made to the specific guidelines from the participating societies, which are in full congruence with this publication.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force behind the 2012 recommendations has chosen to limit the size to the level of the executive summary of previous JTF publications. All relevant reference material is available on the dedicated CVD Prevention Guidelines page of the ESC Website, &lt;a href=&quot;http://www.escardio.org/&quot; title=&quot;ESC Web site&quot;&gt;www.escardio.org&lt;/a&gt;. A one-page summary of all strong recommendations according to the GRADE system will be provided, which may stimulate implementation; and a pocket version will be available for daily clinical use.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Grading of Recommendations Assessment, Development and Evaluation rating system (GRADE) distinguishes quality of evidence and strength of recommendation. Strong evidence does not automatically lead to a strong recommendation. Recommendations are based on the quality of the evidence, the degree of uncertainty about the balance of benefits and harms of the intervention, uncertainty about the values and preferences of patients, and uncertainty about whether the intervention is a wise use of resources. Rather than have a range of classes of recommendation (e.g., Class I&amp;ndash;Class III), GRADE only uses two categories&amp;mdash;&lt;em&gt;strong&lt;/em&gt; or &lt;em&gt;weak&lt;/em&gt; (i.e., discretionary, conditional). The implications of a strong recommendation are: most informed patients would choose the recommended intervention (and request discussion if not offered); clinicians would ensure that most patients should receive the intervention; and the recommendation would be adopted as policy in organized healthcare systems. In contrast, for weak recommendations, some patients would want the intervention but many would not; clinicians would help patients make choices dependent on their values and preferences; policy makers would require debate among various stakeholders to decide on the role of the intervention.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classes of Recommendations (European Society of Cardiology [ESC] System)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Classes of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Classes of Recommendations&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Suggested Wording to Use&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is recommended/is indicated&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Weight of evidence/opinion is in favour of usefulness/efficacy.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Usefulness/efficacy is less well established by evidence/opinion.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;May be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is not recommended&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation (Grading of Recommendations Assessment, Development, and Evaluation [GRADE] System [adapted])&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span&gt;&lt;strong&gt;Strong recommendation&lt;/strong&gt; - Most informed patients would choose the recommended intervention (and request discussion if not offered); clinicians would ensure that most patients should receive the intervention; and the recommendation would be adopted as policy in organized healthcare systems.&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak recommendation&lt;/strong&gt; - Some patients would want the intervention but many would not; clinicians would help patients make choices dependent on their values and preferences; policy makers would require debate among various stakeholders to decide on the role of the intervention.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;According to the National Institute of Health and Clinical Excellence (NICE) Prevention of Cardiovascular Disease: Costing Report (2010), implementation of the population approach may bring numerous savings:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Cost savings from the number of cardiovascular disease (CVD) events avoided. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cost savings associated with CVD such as medications, primary care visits, and outpatient attendances. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cost savings to the wider economy as a result of reduced loss of production due of illness in those of working age, reduced benefit payments, and reduced pension costs from people retiring early from ill health. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Only circulating biomarkers assessed by standardized and validated methods (and identified as risk factors worth translating into clinical practice) were considered in these guidelines, in a context of cost-effectiveness for assessment of individual risk in the general population. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Influenza vaccination as a population-wide prevention measure was associated with a very cost-effective reduction in clinical events. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;After a cardiovascular event, secondary preventive efforts within a structured rehabilitation programme have been shown to be particularly important and cost-effective. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although there is evidence that lifestyle changes are likely to be cost-effective, this needs further evaluation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increasing numbers of patients receiving medications may result in higher healthcare costs. However, modelling strategies to use resources efficiently and to identify 70% of the CVD burden in the UK have reported that prioritizing patients by estimated CVD risk may reduce healthcare costs by &amp;pound;45,000 compared with a diabetes and hypertension first strategy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiac rehabilitation is considered a cost-effective intervention following an acute coronary event; it improves prognosis by reducing recurrent hospitalizations and healthcare expenditure while prolonging life. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investment in additional risk assessment measurements such as imaging with computed tomography to obtain coronary calcium scores may be helpful, but adds considerably to the cost and time involved in risk factor scoring, and its benefit remains unproven. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Once the document had been finalized by the fifth Joint Task Force (JTF) experts it was submitted for extensive independent external review. Following this revision and after acceptance by the European Society of Cardiology (ESC) Committee for Practice Guidelines and the co-operating organizations in the fifth JTF, the document was published.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: The original guideline document differs from 2007 guidelines in several ways: there is a greater focus on new scientific knowledge. The use of grading systems (European Society of Cardiology [ESC] and Grading of Recommendations Assessment, Development, and Evaluation [GRADE]) allows more evidence-based recommendations to be adapted to the needs of clinical practice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The class of recommendations (I-III), levels of evidence (A-C) and categories of GRADE recommendation (strong and weak) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Why Is Prevention of Cardiovascular Disease Needed?&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Atherosclerotic cardiovascular disease (CVD), especially coronary heart disease (CHD), remains the leading cause of premature death worldwide. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CVD affects both men and women; of all deaths that occur before the age of 75 years in Europe, 42% are due to CVD in women and 38% in men. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CVD mortality is changing, with declining age-standardized rates in most European countries, which remain high in Eastern Europe. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevention works: &amp;gt;50% of the reductions seen in CHD mortality relate to changes in risk factors, and 40% to improved treatments. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preventive efforts should be lifelong, from birth (if not before) to old age. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Population and high-risk preventive strategies should be complementary; an approach limited to high-risk persons will be less effective; population education programmes are still needed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Despite gaps in our understanding, there is ample evidence to justify intensive public health and individual preventive efforts. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is still substantial room for improvement in risk factor control, even in individuals at very high risk. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Who Should Benefit from It?&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strategies and Risk Estimation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages*&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In apparently healthy persons, CVD risk is most frequently the result of multiple interacting risk factors. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A risk estimation system such as Systematic Coronary Risk Evaluation Project (SCORE) can assist in making logical management decisions, and may help to avoid both under- and overtreatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Certain individuals are at high CVD risk without needing risk scoring and require immediate intervention for all risk factors. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In younger persons, a low absolute risk may conceal a very high relative risk, and use of the relative risk chart or calculation of their 'risk age' may help in advising them of the need for intensive lifestyle efforts. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;While women appear to be at lower CVD risk than men, this is misleading as risk is deferred by ~10 years rather than avoided. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All risk estimation systems are relatively crude and require attention to qualifying statements. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Additional factors affecting risk can be accommodated in electronic risk estimation systems such as HeartScore (&lt;a href=&quot;http://www.heartscore.org/Pages/welcome.aspx&quot; title=&quot;Heart Score Web site&quot;&gt;www.heartscore.org&lt;/a&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The total risk approach allows flexibility: if perfection cannot be achieved with one risk factor, risk can still be reduced by trying harder with others. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*The detailed SCORE charts with integrated high-density lipoprotein (HDL)-cholesterol values can be found on the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/cvd-prevention.aspx&quot; title=&quot;ESC Web site&quot;&gt;ESC Web site&lt;/a&gt; in the related materials section.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations Regarding Risk Estimation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Total risk estimation using multiple risk factors (such as SCORE) is recommended for asymptomatic adults without evidence of CVD. &lt;strong&gt;(Class of recommendation I, level of evidence C, GRADE rating Strong)&lt;/strong&gt; (Mosca et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;High-risk individuals can be detected on the basis of established CVD, diabetes mellitus, moderate to severe renal disease, very high levels of individual risk factors, or a high SCORE risk, and are a high priority for intensive advice about all risk factors. &lt;strong&gt;(Class of recommendation I, level of evidence C, GRADE rating Strong)&lt;/strong&gt; (Mosca et al., 2007; Graham et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Genetics&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The importance of the familial prevalence of early-onset CVD is not yet sufficiently understood in clinical practice. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Genetic Testing&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Deoxyribonucleic acid (DNA)-based tests for common genetic polymorphisms do not presently add significantly to diagnosis, risk prediction, or patient management and cannot be recommended. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Botkin, 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The added value of genotyping, as an alternative or in addition to phenotyping, for a better management of risk and early prevention in relatives, cannot be recommended. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Paynter et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Age and Gender&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;CVD is by far the biggest cause of death in women. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk of CVD in women, as in men, can be reduced by not smoking, by being active, avoiding overweight, and by having a blood pressure and blood cholesterol check (and intervention, if elevated). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation Regarding Age and Gender&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Women and older people should be included in CVD risk assessments in the same way as other groups to determine need for specific treatments. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Jousilahti et al., 1999; Rayner et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Psychosocial Risk Factors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Low socio-economic status, lack of social support, stress at work and in family life, depression, anxiety, hostility, and the type D personality contribute both to the risk of developing CVD and the worsening of clinical course and prognosis of CVD. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;These factors act as barriers to treatment adherence and efforts to improve lifestyle, as well as to promoting health and well-being in patients and populations. In addition, distinct psychobiological mechanisms have been identified, which are directly involved in the pathogenesis of CVD. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation Regarding Psychosocial Factors&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Psychosocial risk factors should be assessed by clinical interview or standardized questionnaires. Tailored clinical management should be considered in order to enhance quality of life and CHD prognosis. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Rollman et al., 2009; Davidson et al., 2010; Katon et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Other Biomarkers of Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Novel biomarkers have only limited additional value when added to CVD risk assessment with the SCORE algorithm. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High-sensitivity C-reactive protein (CRP) and homocysteine may be used in persons at moderate CVD risk. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Inflammatory Biomarkers&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;High-sensitivity CRP may be measured as part of refined risk assessment in patients with an unusual or moderate CVD risk profile. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Berger et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;High-sensitivity CRP should not be measured in asymptomatic low-risk individuals and high-risk patients to assess 10-year risk of CVD. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Emerging Risk Factors Collaboration et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Fibrinogen may be measured as part of refined risk assessment in patients with an unusual or moderate CVD risk profile. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Fibrinogen Studies Collaboration et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Fibrinogen should not be measured in asymptomatic low-risk individuals and high-risk patients to assess 10-year risk of CVD. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Fibrinogen Studies Collaboration et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Thrombotic Biomarkers&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Homocysteine may be measured as part of a refined risk assessment in patients with an unusual or moderate CVD risk profile. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Clarke et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Homocysteine should not be measured to monitor CVD risk prevention. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Clarke et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Lipoprotein-associated phospholipase 2 (LpPLA2) may be measured as part of a refined risk assessment in patients at high risk of a recurrent acute atherothrombotic event. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Garza et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Imaging Methods in Cardiovascular Disease Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Imaging methods can be relevant in CVD risk assessment in individuals at moderate risk. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations Regarding Imaging Methods&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Measurement of carotid intima-media thickness and/or screening for atherosclerotic plaques by carotid artery scanning should be considered for cardiovascular risk assessment in asymptomatic adults at moderate risk.&lt;strong&gt; (Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (O'Leary et al., 1999; Chambless et al., 1997; Sramek et al., 2000)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Measurement of ankle&amp;ndash;brachial index should be considered for cardiovascular risk assessment in asymptomatic adults at moderate risk. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Hiatt, 2001; McDermott et al., 2002; Vogt et al., 1993)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Computed tomography for coronary calcium should be considered for cardiovascular risk assessment in asymptomatic adults at moderate risk. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Schiffrin, Lipman, &amp;amp; Mann, 2007; Van Werkhoven et al., 2009; Mollmann et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Exercise electrocardiography may be considered for cardiovascular risk assessment in moderate-risk asymptomatic adults (including sedentary adults considering starting a vigorous exercise programme), particularly when attention is paid to non-electrocardiogram markers such as exercise capacity. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Aktas et al., 2004; Gibbons et al., 2003; Kodama et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Other Diseases with Increased Risk for Cardiovascular Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations Regarding Other Diseases with Increased Risk for Cardiovascular Disease&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with chronic kidney disease, risk factors have to be attended to in the same way as for very high-risk persons. &lt;strong&gt;(Class of recommendation I, level of evidence C, GRADE rating Strong)&lt;/strong&gt; (Fox et al., 2010; Colhoun et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All persons with obstructive sleep apnoea should undergo medical assessment, including risk stratification and risk management. &lt;strong&gt;(Class of recommendation IIa, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Gottlieb et al., 2010; Cassar et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All men with erectile dysfunction should undergo medical assessment, including risk stratification and risk management. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Gupta et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;How Can Cardiovascular Disease Prevention Be Used?&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Principles of Behaviour Change&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cognitive-behavioural methods are effective in supporting persons in adopting a healthy lifestyle. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Behavioural Change&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Established cognitive-behavioural strategies (e.g., motivational interviewing) to facilitate lifestyle change are recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Dusseldorp et al., 1999; Rubak et al., 2005)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Specialized healthcare professionals (e.g., nurses, dieticians, psychologists, etc.) should be involved whenever necessary and feasible. &lt;strong&gt;(Class of recommendation IIa, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Gelfand et al., 2006; Clark et al., 2005; Auer et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In individuals at very high CVD risk, multimodal interventions, integrating education on healthy lifestyle and medical resources, exercise training, stress management, and counselling on psychosocial risk factors are recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Dusseldorp et al., 1999; Clark et al., 2005; Linden, Phillips, &amp;amp; Leclerc, 2007; Rees et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Smoking&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Changing smoking behaviour is a cornerstone of improved CVD health. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Public health measures including smoking bans are crucial for the public's perception of smoking as an important health hazard. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations Regarding Smoking&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All smoking is a strong and independent risk factor for CVD and has to be avoided. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Doll et al., 1994; Thun et al., 1997)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Exposure to passive smoking increases risk of CVD and has to be avoided. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (He et al., 1999; Lightwood &amp;amp; Glantz, 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Young people have to be encouraged not to take up smoking. &lt;strong&gt;(Class of recommendation I, level of evidence C, GRADE rating Strong)&lt;/strong&gt; (Centers for Disease Control and Prevention, 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All smokers should be given advice to quit and be offered assistance. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Lancaster &amp;amp; Stead, 2004; Stead et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Nutrition&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A healthy diet has the following characteristics:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Saturated fatty acids to account for &amp;lt;10% of total energy intake, through replacement by polyunsaturated fatty acids &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Trans-unsaturated fatty acids: as little as possible, preferably no intake from processed food, and &amp;lt;1% of total energy intake from natural origin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&amp;lt;5 g of salt per day &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;30&amp;ndash;45 g of fibre per day, from wholegrain products, fruits, and vegetables &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;200 g of fruit per day (2&amp;ndash;3 servings) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;200 g of vegetables per day (2&amp;ndash;3 servings) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fish at least twice a week, one of which to be oily fish &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consumption of alcoholic beverages should be limited to two glasses per day (20 g/day of alcohol) for men and one glass per day (10 g/day of alcohol) for women &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Energy intake should be limited to the amount of energy needed to maintain (or obtain) a healthy weight, i.e., a body mass index (BMI) &amp;lt;25 kg/m&lt;sup&gt;2&lt;/sup&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In general, when following the rules for a healthy diet, no dietary supplements are needed. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation Regarding Nutrition&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A healthy diet is recommended as being the cornerstone of CVD prevention. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Astrup et al., 2011; He et al., 2004; Mozaffarian et al., 2006; Dauchet et al., 2006; He, Nowson, &amp;amp; MacGregor, 2006; Corrao et al., 2004; Sofi et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Physical Activity&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Participation in regular physical activity and/or aerobic exercise training is associated with a decrease in cardiovascular mortality. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations Regarding Physical Activity&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Healthy adults of all ages should spend 2.5&amp;ndash;5 h a week on physical activity or aerobic exercise training of at least moderate intensity, or 1&amp;ndash;2.5 h a week on vigorous intense exercise. Sedentary subjects should be strongly encouraged to start light-intensity exercise programmes. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Talbot et al., 2007; Nocon et al., 2008; Lollgen, Bockenhoff, &amp;amp; Knapp, 2009; Schnohr, Scharling, &amp;amp; Jensen, 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Physical activity/aerobic exercise training should be performed in multiple bouts each lasting &amp;ge;10 min and evenly spread throughout the week, i.e., on 4&amp;ndash;5 days a week. &lt;strong&gt;(Class of recommendation IIa, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Talbot et al., 2007; Nocon et al., 2008; Lollgen, Bockenhoff, &amp;amp; Knapp, 2009; Schnohr, Scharling, &amp;amp; Jensen, 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with previous acute myocardial infarction, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), stable angina pectoris, or stable chronic heart failure should undergo moderate-to-vigorous intensity aerobic exercise training &amp;ge;3 times a week and 30 min per session. Sedentary patients should be strongly encouraged to start light-intensity exercise programmes after adequate exercise-related risk stratification. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Taylor et al., 2004; Piepoli et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Psychosocial Factors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Psychological interventions can counteract psychosocial stress and promote healthy behaviours and lifestyle. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations on the Management of Psychosocial Factors&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Multimodal behavioural interventions, integrating health education, physical exercise, and psychological therapy for psychosocial risk factors and coping with illness, should be prescribed. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Dusseldorp et al., 1999; Clark et al., 2005; Auer et al., 2008; Linden, Phillips, &amp;amp; Leclerc, 2007; Rees et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the case of clinically significant symptoms of depression, anxiety, and hostility, psychotherapy, medication, or collaborative care should be considered. This approach can reduce mood symptoms and enhance health-related quality of life, although evidence for a definite beneficial effect on cardiac endpoints is inconclusive. &lt;strong&gt;(Class of recommendation IIa, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Davidson et al., 2010; Katon et al., 2010; Linden, Phillips, &amp;amp; Leclerc, 2007; Rees et al., 2004; Whalley et al., 2011; Schneiderman et al., 2004; Taylor et al., 2005; Carney et al., 2004; Sauer, Berlin, &amp;amp; Kimmel, 2003)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Body Weight&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Both overweight and obesity are associated with a risk of death in CVD. (Prospective Studies Collaboration et al., 2009; Berrington de Gonzalez et al., 2010; Zheng et al., 2011) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is a positive linear association of BMI with all-cause mortality. (Prospective Studies Collaboration et al., 2009) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All-cause mortality is lowest with a BMI of 20&amp;ndash;25 kg/m&lt;sup&gt;2&lt;/sup&gt;. (Prospective Studies Collaboration et al., 2009; Berrington de Gonzalez et al., 2010; Zheng et al., 2011) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Further weight reduction cannot be considered protective against CVD. (Romero-Corral et al., 2006; Oreopoulos et al., 2008; Hastie et al., 2010; Lavie, Milani, &amp;amp; Ventura, 2009) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation Regarding Body Weight&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Weight reduction in overweight and obese people is recommended as this is associated with favourable effects on blood pressure and dyslipidaemia, which may lead to less CVD. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Prospective Studies Collaboration et al., 2009; Berrington de Gonzalez et al., 2010; Zheng et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Blood Pressure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Elevated blood pressure (BP) is a major risk factor for CHD, heart failure, cerebrovascular disease, peripheral artery disease (PAD), renal failure, and atrial fibrillation. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations on Blood Pressure&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Lifestyle measures such as weight control, increased physical activity, alcohol moderation, sodium restriction, and increased consumption of fruits, vegetables, and low-fat dairy products are recommended in all patients with hypertension and in individuals with high normal BP. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (He, Nowson, &amp;amp; MacGregor, 2006; Sacks et al., 2001; Neter et al., 2003; Cornelissen et al., 2011; McFadden et al., 2005; He &amp;amp; MacGregor, 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All major antihypertensive drug classes (i.e., diuretics, angiotensin-converting enzyme [ACE] inhibitors, calcium antagonists, angiotensin receptor antagonists, and beta-blockers) do not differ significantly in their BP-lowering efficacy and thus should be recommended for the initiation and maintenance of antihypertensive treatment. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Law, Morris, &amp;amp; Wald, 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Beta-blockers and thiazide diuretics are not recommended in hypertensive patients with multiple metabolic risk factors increasing the risk of new-onset diabetes. &lt;strong&gt;(Class of recommendation III, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Poulter et al., 2005; Elliot &amp;amp; Meyer, 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with diabetes, an ACE inhibitor or a renin&amp;ndash;angiotensin receptor blocker is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Patel et al., 2007; Turnbull et al., 2005; Viberti, Wheeldon &amp;amp; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators, 2002)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Risk stratification using the SCORE risk chart is recommended as a minimal requirement in each hypertensive patient. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Conroy et al., 2003; Sehestedt et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;However, as there is evidence that subclinical organ damage predicts cardiovascular death independently of SCORE, a search for subclinical organ damage should be encouraged, particularly in individuals at low or moderate risk (SCORE 1&amp;ndash;4%). &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Conroy et al., 2003; Sehestedt et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Drug treatment is recommended to be initiated promptly in patients with grade 3 hypertension, as well as in patients with grade 1 or 2 hypertension who are at high or very high total cardiovascular risk. &lt;strong&gt;(Class of recommendation I, level of evidence C, GRADE rating Strong)&lt;/strong&gt; (Mancia et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with grade 1 or 2 hypertension and at moderate total cardiovascular risk, drug treatment may be delayed for several weeks, and in grade 1 hypertensive patients without any other risk factor, for several months while trying lifestyle measures. &lt;strong&gt;(Class of recommendation IIb, level of evidence C, GRADE rating Weak)&lt;/strong&gt; (Mancia et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systolic BP should be lowered to &amp;lt;140 mmHg (and diastolic BP &amp;lt;90 mmHg) in all hypertensive patients. &lt;strong&gt;(Class of recommendation IIa, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Zanchetti, Grassi, &amp;amp; Mancia, 2009; Liu et al., 2005; Weber et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All hypertensive patients with established cardiovascular disease, or with type 2 diabetes, or with an estimated 10-year risk of cardiovascular death &amp;ge;5% (based on the SCORE chart) should be considered for statin therapy. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Blackburn et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Antiplatelet therapy, in particular low-dose aspirin, is recommended for hypertensive patients with cardiovascular events. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong) &lt;/strong&gt;(Turnbull et al., 2005)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Antiplatelet therapy may be considered in hypertensive patients without a history of cardiovascular disease, but with reduced renal function or at high cardiovascular risk. &lt;strong&gt;(Class of recommendation IIb, level of evidence A, GRADE rating Weak)&lt;/strong&gt; (Zanchetti et al., 2002; Ruilope et al., 2001; Jardine et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment Targets in Patients with Type 2 Diabetes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Intensive management of hyperglycaemia in diabetes reduces the risk of microvascular complications and, to a lesser extent, that of cardiovascular disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intensive treatment of BP in diabetes reduces the risk of macrovascular and microvascular outcomes. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Multiple antihypertensive drugs are usually required to reach the target. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations on Diabetes Mellitus&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The target glycated haemoglobin (HbA&lt;sub&gt;1c&lt;/sub&gt;) for the prevention of CVD in diabetes of &amp;lt;7.0% (&amp;lt;53 mmol/mol) is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (U.K. Prospective Diabetes Study [UKPDS] Group, &quot;Intensive blood-glucose control,&quot; 1998; ADVANCE Collaborative Group et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Statins are recommended to reduce cardiovascular risk in diabetes. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Colhoun et al., 2004; Collins et al., 2003)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Hypoglycaemia and excessive weight gain must be avoided and individual approaches (both targets and drug choices) may be necessary in patients with complex disease. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (ADVANCE Collaborative Group et al., 2008; Heidenreich et al., 2011; Duckworth et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Metformin should be used as first-line therapy if tolerated and not contraindicated. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (&quot;Effect of intensive blood-glucose control,&quot; 1998)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Further reductions in HbA&lt;sub&gt;1c&lt;/sub&gt; to a target of &amp;lt;6.5% (&amp;lt;48 mmol/mol) (the lowest possible safely reached HbA&lt;sub&gt;1c&lt;/sub&gt;) may be useful at diagnosis. For patients with a long duration of diabetes this target may reduce risk of microvascular outcomes. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (ADVANCE Collaborative Group et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;BP targets in diabetes are recommend to be &amp;lt;140/80 mmHg. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Hansson et al., 1998; UKPDS Group, &quot;Tight blood pressure control,&quot; 1998)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Target LDL cholesterol is &amp;lt;2.5 mmol/L, for patients without atherosclerotic disease total cholesterol may be &amp;lt;4.5 mmol/L, with a lower LDL cholesterol target of &amp;lt;1.8 mmol/L (using higher doses of statins) for diabetic patients at very high CVD risk. &lt;strong&gt;(Class of recommendation IIb, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Shepherd et al., 2006)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Antiplatelet therapy with aspirin is not recommended for people with diabetes who do not have clinical evidence of atherosclerotic disease. &lt;strong&gt;(Class of recommendation III, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (De Berardis et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Lipids&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Increased plasma cholesterol and LDL cholesterol are among the main risk factors for CVD. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertriglyceridaemia and low HDL cholesterol are independent CVD risk factors. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Statin therapy has a beneficial effect on atherosclerotic CVD outcomes. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations on Management of Hyperlipidaemia&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The recommended target levels are &amp;lt;5 mmol/L (less than ~190 mg/dL) for total plasma cholesterol and &amp;lt;3 mmol/L (less than ~115 mg/dL) for LDL cholesterol for subjects at low or moderate risk. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Neaton et al., 1992; Smith et al., 1992)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients at high CVD risk, an LDL cholesterol goal &amp;lt;2.5 mmol/L (less than ~100 mg/dL) is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Cholesterol Treatment Trialists' [CTT] Collaboration et al., 2010; Brugts et al., 2009; Mills et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients at very high CVD risk, the recommended LDL cholesterol target is &amp;lt;1.8 mmol/L (less than ~70 mg/dL) or a &amp;ge;50% LDL cholesterol reduction when the target level cannot be reached. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (CTT Collaboration et al., 2010; Pedersen et al., 2005; LaRosa et al., 2005)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All patients with familial hypercholesterolaemia must be recognized as high-risk patients and be treated with lipid-lowering therapy. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Neil et al., 2008; Jensen, Blankenhorn, &amp;amp; Kornerup, 1967)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with an acute coronary syndrome (ACS), statin treatment in high doses has to be initiated while the patients are in hospital. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Schwartz et al., 2001; Ray et al., 2005; de Lemos et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prevention of non-haemorrhagic stroke: treatment with statins must be started in all patients with established atherosclerotic disease and in patients at high risk for developing CVD. Treatment with statins must be started in patients with a history of non-cardioembolic ischaemic stroke. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Amarenco &amp;amp; Labreuche, 2009; Byington et al., 2001)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Occlusive arterial disease of the lower limbs and carotid artery disease are CHD risk-equivalent conditions and lipid-lowering therapy is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Ankle Brachial Index Collaboration et al., 2008; Aung et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Statins should be considered as the first-line drugs in transplant patients with dyslipidaemia. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Navaneethan et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Chronic kidney disease (stages 2&amp;ndash;5, i.e., glomerular filtration rate [GFR] &amp;lt;90 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) is acknowledged as a CHD risk-equivalent and the LDL cholesterol target in these patients should be adapted to the degree of renal failure. &lt;strong&gt;(Class of recommendation IIa, level of evidence C, GRADE rating Strong)&lt;/strong&gt; (Sandhu et al., 2006)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Intervention Strategies as a Function of Total Cardiovascular Risk and Low-density Lipoprotein Cholesterol Level&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Intervention Strategies as a Function of Total Cardiovascular Risk and Low-density Lipoprotein Cholesterol Level&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Total CV risk (SCORE) %&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;5&quot;&gt;LDL-C levels&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;70 mg/dL&lt;br /&gt;&#xD;&#xA;            &amp;lt;1.8 mmol/L&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;70 to &amp;lt;100 mg/dL&lt;br /&gt;&#xD;&#xA;            1.8 to &amp;lt;2.5 mmol/L&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;100 to &amp;lt;155 mg/dL&lt;br /&gt;&#xD;&#xA;            2.5 to &amp;lt;4.0 mmol/L&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;155 to &amp;lt;190 mg/dL&lt;br /&gt;&#xD;&#xA;            4.0 to &amp;lt;4.9 mmol/L&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;gt;190 mg/dL&lt;br /&gt;&#xD;&#xA;            &amp;gt;4.9 mmol/L&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No lipid intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No lipid intervention &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug if uncontrolled&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class of recommendation/Level of evidence&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;ge;1 to &amp;lt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug if uncontrolled&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug if uncontrolled&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug if uncontrolled&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class of recommendation/Level of evidence&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/A&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;5 to &amp;lt;10, or high risk&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class of recommendation/Level of evidence&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/A&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;ge;10 or very high risk&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention, consider drug*&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle intervention and immediate drug intervention&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class of recommendation/Level of evidence&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IIa/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I/A&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;From: European Association for Cardiovascular Prevention &amp;amp; Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769&amp;ndash;1818.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;CV, cardiovascular; LDL-C, low-density lipoprotein; SCORE, systematic coronary risk evaluation project.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antithrombotics&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations on Antithrombotic Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the acute phase of coronary artery syndromes and for the following 12 months, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin is recommended unless contraindicated due to factors such as an increased risk of bleeding. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Wiviott et al., 2007; Gurbel et al., 2009; Wallentin et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clopidogrel (600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Chen et al., 2005; Yusuf et al., 2001)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the chronic phase (&amp;gt;12 months) after myocardial infarction, aspirin is recommended for secondary prevention. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Antithrombotic Trialists' Collaboration, 2002; Antithrombotic Trialists' [ATT] Collaboration et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with non-cardioembolic transient ischaemic attack or ischaemic stroke, secondary prevention with either dipyridamole plus aspirin or clopidogrel alone is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Sacco et al., 2008; CAPRIE Steering Committee, 1996; Diener et al., 2004; De Schryver, Algra, &amp;amp; van Gijn, 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the case of intolerance to dipyridamole (headache) or clopidogrel, aspirin alone is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Antithrombotic Trialists' Collaboration, 2002; ATT Collaboration et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with non-cardioembolic cerebral ischaemic events, anticoagulation is not superior to aspirin and is not recommended. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (Mohr et al., 2001; Liu, Counsell, &amp;amp; Sandercock, 2000)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aspirin or clopidogrel cannot be recommended in individuals without cardiovascular or cerebrovascular disease due to the increased risk of major bleeding. &lt;strong&gt;(Class of recommendation III, level of evidence B, GRADE rating Weak)&lt;/strong&gt; (ATT Collaboration et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Adherence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adherence to medication in individuals at high risk and in patients with CVD is still low. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Several types of interventions are effective in improving medication adherence. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations on Patients' Adherence&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Physicians must assess adherence to medication, and identify reasons for non-adherence in order to tailor further interventions to the individual needs of the patient or person at risk. &lt;strong&gt;(Class of recommendation I, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Ho, Bryson, &amp;amp; Rumsfeld, 2009; Osterberg &amp;amp; Blaschke, 2005; Kripalani, Yao, &amp;amp; Haynes, 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In clinical practice, reducing dosage demands to the lowest acceptable level is recommended. In addition, repetitive monitoring and feedback should be implemented. If feasible, multisession or combined behavioural interventions should be offered in the case of persistent non-adherence. &lt;strong&gt;(Class of recommendation IIa, level of evidence A, GRADE rating Strong)&lt;/strong&gt; (Kripalani, Yao, &amp;amp; Haynes, 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to Table 19 in the original guideline document for recommendations for promoting medication adherence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Where Should Programmes Be Offered?&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular disease is the single most important cause of death for both men and women and can often be prevented! &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation on Program Provision&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Actions to prevent cardiovascular disease should be incorporated into everyone's daily lives, starting in early childhood and continuing throughout adulthood and senescence. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Weintraub et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cardiovascular Disease Prevention in Primary Care: Role of Nurses&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Nurse-coordinated prevention programmes are effective across a variety of practice settings. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation on Nurse-Coordinated Care&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nurse-coordinated prevention programmes should be well integrated into healthcare systems. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Wood et al., 2008; Berra, Miller, &amp;amp; Fair, 2006; Berra et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cardiovascular Disease Prevention in General Practice&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk factor screening including the lipid profile may be considered in adult men &amp;ge;40 years old and in women &amp;ge;50 years of age or post-menopausal (European Association for Cardiovascular Prevention &amp;amp; Rehabilitation et al., 2011) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The physician in general practice is the key person to initiate, coordinate, and provide long-term follow-up for CVD prevention (Zhao et al., 2007) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cardiovascular Disease Prevention in Primary Care: Role of the Cardiologist&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Messages&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The practicing cardiologist should be the advisor in cases where there is uncertainty over the use of preventive medication or when usual preventive options are difficult to apply (Mosca et al., 2011; Heidenreich et al., 2011; Redberg et al., 2009) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The practicing cardiologist should regularly review the discharge recommendations of the hospital after a cardiac event or intervention (Mosca et al., 2011; Heidenreich et al., 2011; Redberg et al., 2009) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Primary Care-Based Self-Help Programmes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation on Self-Help Programmes&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with cardiac disease may participate in self-help programmes to increase or maintain awareness of the need for risk factor management, for maintaining physical fitness, or for diligent self-management of oral anticoagulation. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Matchar et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hospital-Based Programmes: Hospital Services&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation on Hospital-Based Programmes&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All patients with cardiovascular disease must be discharged from hospital with clear guideline-oriented treatment recommendations to minimize adverse events. &lt;strong&gt;(Class of recommendation I, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Chow et al., 2010; Bramlage et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hospital-Based Programmes: Specialized Prevention Centres&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendation for Specialized Prevention Centres&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All patients requiring hospitalization or invasive intervention after an acute ischaemic event should participate in a cardiac rehabilitation programme to improve prognosis by modifying lifestyle habits and increasing treatment adherence. &lt;strong&gt;(Class of recommendation IIa, level of evidence B, GRADE rating Strong)&lt;/strong&gt; (Piepoli et al., 2010; Chow et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Non-governmental Organization Programmes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Non-governmental organizations are important partners to healthcare workers in promoting preventive cardiology. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Action at the European Political Level&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Key Message&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The European Heart Health Charter marks the start of a new era of political engagement in preventive cardiology. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence (European Society of Cardiology [ESC] System)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from multiple randomized clinical trials or meta-analyses.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from a single randomized clinical trial or large non-randomized studies.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus of opinion of the experts and/or small studies, retrospective studies, registries.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classes of Recommendations (ESC System)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Classes of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Classes of Recommendations&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Suggested Wording to Use&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is recommended/is indicated&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Weight of evidence/opinion is in favour of usefulness/efficacy.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Usefulness/efficacy is less well established by evidence/opinion.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;May be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is not recommended&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation (Grading of Recommendations Assessment, Development, and Evaluation [GRADE] System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong recommendation&lt;/strong&gt; - Most informed patients would choose the recommended intervention (and request discussion if not offered); clinicians would ensure that most patients should receive the intervention; and the recommendation would be adopted as policy in organized healthcare systems.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak recommendation&lt;/strong&gt; - Some patients would want the intervention but many would not; clinicians would help patients make choices dependent on their values and preferences; policy makers would require debate among various stakeholders to decide on the role of the intervention.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Modified World Health Organization (WHO) smoking cessation algorithm is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18539916&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Aktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA. 2004 Sep 22;292(12):1462-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15383517&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009 May;8(5):453-63. [62 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19375663&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008 Jul 9;300(2):197-208. [48 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18612117&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19482214&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11786451&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Astrup A, Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU, Kok FJ, Krauss RM, Lecerf JM, LeGrand P, Nestel P, Riserus U, Sanders T, Sinclair A, Stender S, Tholstrup T, Willett WC. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010. Am J Clin Nutr. 2011 Apr;93(4):684-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21270379&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Auer R, Gaume J, Rodondi N, Cornuz J, Ghali WA. Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis. Circulation. 2008 Jun 17;117(24):3109-17. [49 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18541742&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007;(4):CD000123. [91 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17943736&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010 Mar 23;55(12):1169-77. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20298922&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berra K, Fletcher BJ, Hayman LL, Miller NH. Global cardiovascular disease prevention: a call to action for nursing: the global burden of cardiovascular disease. J Cardiovasc Nurs. 2011 Jul-Aug;26(4 Suppl):S1-2. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21659807&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berra K, Miller NH, Fair JM. Cardiovascular disease prevention and disease management: a critical role for nursing. J Cardiopulm Rehabil. 2006 Jul-Aug;26(4):197-206. [39 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16926682&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21121834&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Blackburn DF, Lamb DA, Eurich DT, Johnson JA, Wilson TW, Dobson RT, Blackburn JL. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J Hypertens. 2007 Jul;25(7):1499-505. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17563574&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Botkin JR. Informed consent for genetic research. Curr Protoc Hum Genet. 2010 Jul;Chapter 1:Unit 1.16. [50 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20582914&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U. The effect of optimal medical therapy on 1-year mortality after acute myocardial  infarction. Heart. 2010 Apr;96(8):604-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20353936&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but  with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. [37 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19567909&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001 Jan 23;103(3):387-92. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11157690&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 Nov 16;348(9038):1329-39. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8918275&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab PG, Kaufmann PG, Czajkowski SM, Jaffe AS, ENRICHD Investigators. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med. 2004 Jul-Aug;66(4):466-74. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15272090&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cassar A, Morgenthaler TI, Lennon RJ, Rihal CS, Lerman A. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol. 2007 Oct 2;50(14):1310-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17903628&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centers for Disease Control and Prevention. How tobacco smoke causes disease: the biology and behavioural basis for smoking-attributable disease. A report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention; 2010. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC)  Study, 1987-1993. Am J Epidemiol. 1997 Sep 15;146(6):483-94. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9290509&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative . Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1607-21. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16271642&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21067804&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010 Feb 16;121(6):750-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20124123&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005 Nov 1;143(9):659-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16263889&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R, B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010 Oct 11;170(18):1622-31. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20937919&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685-96. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15325833&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814710&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE  project. Eur Heart J. 2003 Jun;24(11):987-1003. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12788299&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011 Nov;58(5):950-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21896934&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004 May;38(5):613-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15066364&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr. 2006 Oct;136(10):2588-93. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16988131&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, Albanese G, Kronish I, Hegel M, Burg MM. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010 Apr 12;170(7):600-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20386003&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes:  meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531. [32 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19897665&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 Sep 15;292(11):1307-16. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15337732&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2007;(3):CD001820. [54 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17636684&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004 Jul 24-30;364(9431):331-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15276392&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994 Oct 8;309(6959):901-11. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7755693&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19092145&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dusseldorp E, van Elderen T, Maes S, Meulman J, Kraaij V. A meta-analysis of psychoeduational programs for coronary heart disease patients. Health Psychol. 1999 Sep;18(5):506-19. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10519467&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9742977&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 Jan 20;369(9557):201-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17240286&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and  mortality: an individual participant meta-analysis. Lancet. 2010 Jan 9;375(9709):132-40. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20031199&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;European Association for Cardiovascular Prevention &amp; Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the  European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32(14):1769-818. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21712404&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fibrinogen Studies Collaboration, Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies [trunc]. Am J Epidemiol. 2007 Oct 15;166(8):867-79. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17785713&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD, Acute Coronary Treatment and Intervention Outcomes Network registry. Use of evidence-based therapies in short-term outco. Circulation. 2010 Jan 26;121(3):357-65. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20065168&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007 Feb;82(2):159-65. [38 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17290721&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17032986&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2003 Jan 7;107(1):149-58. [62 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12515758&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease  and heart failure: the sleep heart health study. Circulation. 2010 Jul 27;122(4):352-60. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20625114&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A, European Society of Cardiology (ESC), European Association for Cardiovascular Prevention and Rehabilitation (EACPR), Council on Cardiovascular Nursing, European Association for Study of Diabetes (EASD), International Diabetes Federation Europe (IDF-Europe), European Stroke Initiative (EUSI), International Society of Behavioural Medicine (ISBM), European Society of Hypertension (ESH), WONCA Europe (European Society of General Practice/Family Medicine), European Heart Network (EHN), European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies [trunc]. Eur J Cardiovasc Prev Rehabil. 2007 Sep;14(Suppl 2):S1-113. [1105 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17726407&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on  erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011 Nov 14;171(20):1797-803. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911624&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery  disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19923168&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9635947&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hastie CE, Padmanabhan S, Slack R, Pell AC, Oldroyd KG, Flapan AD, Jennings KP, Irving J, Eteiba H, Dominiczak AF, Pell JP. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous  coronary intervention. Eur Heart J. 2010 Jan;31(2):222-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19687163&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2011 Jul 30;378(9789):380-2. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21803192&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006 Jan 28;367(9507):320-6. [31 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16443039&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med. 1999 Mar 25;340(12):920-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10089185&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, Greenland P. Accumulated evidence on fish consumption and coronary heart disease mortality: a  meta-analysis of cohort studies. Circulation. 2004 Jun 8;109(22):2705-11. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15184295&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ, American Heart Association Advocacy Coordinating Committee, Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011 Mar 1;123(8):933-44. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21262990&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001 May 24;344(21):1608-21. [125 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11372014&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009 Jun 16;119(23):3028-35. [79 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19528344&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010 Sep 14;56(12):956-65. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20828648&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jensen J, Blankenhorn DH, Kornerup V. Coronary disease in familial hypercholesterolemia. Circulation. 1967 Jul;36(1):77-82. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6027217&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective  follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999 Mar 9;99(9):1165-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10069784&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010 Dec 30;363(27):2611-20. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190455&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, Yamada N, Sone H. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and  cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009 May 20;301(19):2024-35. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19454641&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007 Mar 26;167(6):540-9. [56 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17389285&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000165. [110 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15494989&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 7;352(14):1425-35. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15755765&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009 May 26;53(21):1925-32. [87 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19460605&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. [60 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19454737&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lightwood JM, Glantz SA. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation. 2009 Oct 6;120(14):1373-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19770392&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Linden W, Phillips MJ, Leclerc J. Psychological treatment of cardiac patients: a meta-analysis. Eur Heart J. 2007 Dec;28(24):2972-84. [78 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17984133&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005 Dec;23(12):2157-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16269957&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient  ischaemic attack. Cochrane Database Syst Rev. 2000;(2):CD000248. [13 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10796334&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med. 2009 Mar;30(3):213-24. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19199202&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007 Sep;25(9):1751-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17762635&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P, THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010 Oct 21;363(17):1608-20. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20961244&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C, Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002 Jun 18;136(12):873-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12069561&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;McFadden CB, Brensinger CM, Berlin JA, Townsend RR. Systematic review of the effect of daily alcohol intake on blood pressure. Am J Hypertens. 2005 Feb;18(2 Pt 1):276-86. [40 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15752957&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008 Nov 25;52(22):1769-81. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19022156&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001 Nov 15;345(20):1444-51. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11794192&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mollmann H, Liebetrau C, Nef HM, Hamm CW. The Swedish paradox: or is there really no gender difference in acute coronary syndromes. Eur Heart J. 2011 Dec;32(24):3070-2. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22003153&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK, Expert Panel/Writing Group, American Heart Association, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, American College of Cardiology Foundation, Society of Thoracic Surgeons, American Medical Women's Association, Centers for Disease Control and Prevention, Office of Research on Women's Health, Association of Black Cardiologists, American College of Physicians, World Heart Federation, National Heart, Lung, and Blood Institute, American College of Nurse Practitioners. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007 Mar 20;115(11):1481-501. [23 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17309915&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Pina IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. Circulation. 2011 Mar 22;123(11):1243-62. [142 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21325087&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006 Apr 13;354(15):1601-13. [83 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16611951&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2009;(2):CD005019. [52 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19370615&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jul;152(7):1490-500. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1627030&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008 Nov;29(21):2625-33. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18840879&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003 Nov;42(5):878-84. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12975389&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nocon M, Hiemann T, Muller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2008 Jun;15(3):239-46. [39 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18525377&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative  Research Group. N Engl J Med. 1999 Jan 7;340(1):14-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9878640&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity (Silver Spring). 2008 Feb;16(2):442-50. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18239657&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487-97. [127 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16079372&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 Sep 8;370(9590):829-40. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17765963&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Paynter NP, Chasman DI, Pare G, Buring JE, Cook NR, Miletich JP, Ridker PM. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010 Feb 17;303(7):631-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20159871&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL). High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437-45. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16287954&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AD, Schmid JP, Cardiac Rehabilitation Section of the European Association of Cardiovascular. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010 Feb;17(1):1-17. [54 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19952757&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004 Jan 24;328(7433):189. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14729656&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S, ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005 Sep 10-16;366(9489):907-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16154017&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009 Mar 28;373(9669):1083-96. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19299006&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E, PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16226162&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rayner M, Allender S, Scarborough P, British Heart Foundation Health Promotion Research Group. Cardiovascular disease in Europe. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(Suppl 2):S43-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19675436&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW, American Academy of Family Physicians, American Association of Cardiovascular and Pulmonary Rehabilitation, Preventive Cardiovascular Nurses Association. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology/ American Heart Association task force on performance measures [trunc]. Circulation. 2009 Sep 29;120(13):1296-336. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19770388&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rees K, Bennett P, West R, Davey SG, Ebrahim S. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2004;(2):CD002902. [111 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15106183&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, Kapoor WN, Schulberg HC, Reynolds CF 3rd. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA. 2009 Nov 18;302(19):2095-103. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19918088&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. Association of bodyweight with total mortality and with cardiovascular events in  coronary artery disease: a systematic review of cohort studies. Lancet. 2006 Aug 19;368(9536):666-78. [74 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920472&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005 Apr;55(513):305-12. [81 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15826439&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001 Feb;12(2):218-25. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11158211&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18753638&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11136953&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006 Jul;17(7):2006-16. [69 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16762986&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003 Jul 8;108(1):32-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12821544&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007 Jul 3;116(1):85-97. [124 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17606856&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schneiderman N, Saab PG, Catellier DJ, Powell LH, DeBusk RF, Williams RB, Carney RM, Raczynski JM, Cowan MJ, Berkman LF, Kaufmann PG, ENRICHD Investigators. Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. Psychosom Med. 2004 Jul-Aug;66(4):475-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15272091&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schnohr P, Scharling H, Jensen JS. Intensity versus duration of walking, impact on mortality: the Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil. 2007 Feb;14(1):72-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17301630&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 4;285(13):1711-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11277825&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt P, Olsen MH. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010 Apr;31(7):883-91. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20034972&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New  Targets (TNT) study. Diabetes Care. 2006 Jun;29(6):1220-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16731999&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA. 1992 Jan 1;267(1):70-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1727199&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010 Nov;92(5):1189-96. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20810976&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sramek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of  intima-media thickness measurements in carotid and femoral arteries. Invest Radiol. 2000 Dec;35(12):699-706. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11204795&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000146. [277 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18253970&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Talbot LA, Morrell CH, Fleg JL, Metter EJ. Changes in leisure time physical activity and risk of all-cause mortality in men  and women: the Baltimore Longitudinal Study of Aging. Prev Med. 2007 Aug-Sep;45(2-3):169-76. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17631385&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS, ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005 Jul;62(7):792-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15997021&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004 May 15;116(10):682-92. [75 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15121495&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Thun MJ, Myers DG, Day-Lally C, Namboodin MM, Calle EE, Flanders WD, Adams SL, Heath CW. Age and the exposure-response relationships between cigarette smoking and premature death in Cancer Prevention Study II. Changes in cigarette-related disease risks and heir implications for prevention and control. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1997. 383-413 p.&amp;nbsp;(Smoking and tobacco control monograph; no. 8).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005 Jun 27;165(12):1410-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15983291&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9742976&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published erratum appears in BMJ 1999 Jan 2;318(7175):29]. BMJ. 1998 Sep 12;317(7160):703-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9732337&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Van Werkhoven JM, Gaemperli O, Schuijf JD, Jukema JW, Kroft LJ, Leschka S, Alkadhi H, Valenta I, Pundziute G, De Roos A, Van Der Wall EE, Kaufmann PA, Bax JJ. Multislice computed tomography coronary angiography for risk stratification in patients with an intermediate pretest likelihood. Heart. 2009 Oct;95(19):1607-11. [33 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19581272&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 Aug 6;106(6):672-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12163426&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993 Jul 28;270(4):465-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8320785&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19717846&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004 Jun 19;363(9426):2049-51. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15207957&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL, Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP, American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular Disease in the Young, Council on the Kidney in Cardiovascular Disease, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Clinical Cardiology, and Stroke Council. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011 Aug 23;124(8):967-90. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21788592&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, West R, Moxham T, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2011;(8):CD002902. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21833943&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17982182&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study Group. Nurse-. Lancet. 2008 Jun 14;371(9629):1999-2012. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18555911&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11519503&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009 May;27(5):923-34. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19381107&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I, Wedel H, HOT Study Group. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002 Nov;20(11):2301-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12409970&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zhao L, Kolm P, Borger MA, Zhang Z, Lewis C, Anderson G, Jurkovitz CT, Borkon AM, Lyles RH, Weintraub WS. Comparison of recovery after mitral valve repair and replacement. J Thorac Cardiovasc Surg. 2007 May;133(5):1257-63. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17467438&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta PC, Ramadas K, Tsugane S, Irie F, Tamakoshi A, Gao YT, Wang R, Shu XO, Tsuji I, Kuriyama S, Tanaka H, Satoh H, Chen CJ, Yuan JM, Yoo KY, Ahsan H, Pan WH, Gu D, Pednekar MS, Sauvaget C, Sasazuki S, Sairenchi T, Yang G, Xiang YB, Nagai M, Suzuki T, Nishino Y, You SL, Koh WP, Park SK, Chen Y, Shen CY, Thornquist M, Feng Z, Kang D, Boffetta P, Potter JD. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011 Feb 24;364(8):719-29. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21345101&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Reduction in the incidence of first or recurrent clinical events due to coronary heart disease, ischaemic stroke, and peripheral artery disease&lt;/li&gt;&#xA;    &lt;li&gt;Prevention of disability and early death&lt;/li&gt;&#xA;    &lt;li&gt;Prevention of clinical cardiovascular disease&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Smoking Cessation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Side effects of varenicline are rare, but, due to links with serious adverse events, including depressed mood, agitation, and suicidal thoughts, a psychiatric history and suicide risk assessment should be taken before prescription. Small but significantly increased risk of cardiovascular events associated with the use of varenicline was reported. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All pharmacological smoking-cessation therapies should be used short term since long-term safety and efficacy data are lacking. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antihypertensive Drugs&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Beta-blockers induce weight gain, have adverse effects on lipid metabolism, and increase (compared with other drugs) the incidence of new-onset diabetes; they should not be preferred in hypertensive patients with multiple metabolic risk factors (i.e., abdominal obesity, impaired fasting glucose, and impaired glucose tolerance), conditions that increase the risk of new-onset diabetes. This also applies to thiazide diuretics, which have dyslipidaemic and diabetogenic effects, particularly when used at high doses.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Lipid-lowering Drugs&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Higher activity of liver enzymes in plasma occurs occasionally with use of statins, and in most cases is reversible: 5% to 10% of patients receiving statins develop myopathy, but rhabdomyolysis is extremely rare. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Because statins are prescribed on a long-term basis, possible interactions with other drugs deserve particular and continuous attention, as many patients will receive pharmacological therapy for concomitant conditions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There are reports indicating increased blood sugar and glycated haemoglobin (HbA&lt;sub&gt;1c&lt;/sub&gt;) levels, i.e., increased risk of type 2 diabetes, as a possible adverse effect of long-term statin therapy, but the benefits of statins far outweigh the risks for the vast majority of patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Flushing is the main adverse effect of niacin, which may affect compliance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other drugs metabolized through cytochrome P450 should be avoided when a combination of a fibrate and statin is prescribed (see Table 17 in the original guideline document). Fibrates should preferably be taken in the morning and statins in the evening to minimize peak dose concentrations and decrease the risk of myopathy. Patients have to be instructed about warning symptoms (myalgia) even though these adverse effects are very rare. Avoiding the addition of gemfibrozil to a statin regimen is advised. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antithrombotic Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Risk of major bleeding&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin is contraindicated in patients with excessive risk of bleeding.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, over-ride the individual responsibility of health professionals to make appropriate decisions in the circumstance of the individual patients in consultation with that patient, and, where appropriate and necessary, the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach can be applied to diagnostic strategies in the same way with a few minor changes to the quality criteria used, and may also be used in conjunction with appraisals of resource use and cost-effectiveness. However, as resources are valued differently across Europe, it is not feasible in these guidelines to make judgements about the appropriateness of resource use for the interventions and diagnostic strategies considered here. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Task Force behind the 2012 recommendations has chosen to limit the size to the level of the executive summary of previous Joint Task Force (JTF) publications. All relevant reference material is available on the dedicated cardiovascular disease (CVD) Prevention Guidelines page of the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;. A one-page summary of all strong recommendations according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system will be provided, which may stimulate implementation; and a pocket version will be available for daily clinical use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The partner societies co-operate in the Joint Societies Implementation Committee, which aims to stimulate dissemination of the guidelines, acceptance at national levels, and the formation of national alliances to translate the recommendations into clinical practice. The programme 'Call for Action' was one of the efforts of this committee. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation has been well accepted at the European Union (EU) political level after the launch of the European Heart Health Charter in the European Parliament in June 2007. This public health statement has been endorsed by a majority of the EU member states, defining the characteristics of people who tend to stay healthy as:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;No use of tobacco &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adequate physical activity: at least 30 min five times a week &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Healthy eating habits &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;No overweight &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Blood pressure below 140/90 mmHg &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Blood cholesterol below 5 mmol/L (190 mg/dL) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Normal glucose metabolism &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Avoidance of excessive stress &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Pocket Guide/Reference Cards" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Slide Presentation" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012 Jul;33(13):1635-701. [568 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22555213&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2003 Dec (revised 2012 Jul)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="European Society of Cardiology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The preparation and publication of this report was supported financially by the European Society of Cardiology (ESC) without any involvement of the pharmaceutical industry.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors/Task Force Members&lt;/em&gt;: Joep Perk (&lt;em&gt;Chairperson&lt;/em&gt;) (Sweden), Guy De Backer&lt;sup&gt;1&lt;/sup&gt; (Belgium), Helmut Gohlke&lt;sup&gt;1&lt;/sup&gt; (Germany), Ian Graham&lt;sup&gt;1&lt;/sup&gt; (Ireland), Željko Reiner&lt;sup&gt;2&lt;/sup&gt; (Croatia), W.M. Monique Verschuren1 (The Netherlands), Christian Albus&lt;sup&gt;3&lt;/sup&gt; (Germany), Pascale Benlian&lt;sup&gt;1&lt;/sup&gt; (France), Gudrun Boysen&lt;sup&gt;4&lt;/sup&gt; (Denmark), Renata Cifkova&lt;sup&gt;5&lt;/sup&gt; (Czech Republic), Christi Deaton&lt;sup&gt;1&lt;/sup&gt; (UK), Shah Ebrahim&lt;sup&gt;1&lt;/sup&gt; (UK), Miles Fisher&lt;sup&gt;6&lt;/sup&gt; (UK), Giuseppe Germano&lt;sup&gt;1&lt;/sup&gt; (Italy), Richard Hobbs&lt;sup&gt;1,7&lt;/sup&gt; (UK), Arno Hoes&lt;sup&gt;7&lt;/sup&gt; (The Netherlands), Sehnaz Karadeniz&lt;sup&gt;8&lt;/sup&gt; (Turkey), Alessandro Mezzani&lt;sup&gt;1&lt;/sup&gt; (Italy), Eva Prescott&lt;sup&gt;1&lt;/sup&gt; (Denmark), Lars Ryden&lt;sup&gt;1&lt;/sup&gt; (Sweden), Martin Scherer&lt;sup&gt;7&lt;/sup&gt; (Germany), Mikko Syv&amp;auml;nne&lt;sup&gt;9&lt;/sup&gt; (Finland), Wilma J.M. Scholte Op Reimer&lt;sup&gt;1 &lt;/sup&gt;(The Netherlands), Christiaan Vrints&lt;sup&gt;1 &lt;/sup&gt;(Belgium), David Wood&lt;sup&gt;1&lt;/sup&gt; (UK), Jose Luis Zamorano&lt;sup&gt;1&lt;/sup&gt; (Spain), Faiez Zannad&lt;sup&gt;1&lt;/sup&gt; (France)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Expert who contributed to parts of the guidelines&lt;/em&gt;: Marie Therese Cooney (Ireland)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;ESC Committee for Practice Guidelines (CPG) Members&lt;/em&gt;: Jeroen Bax (&lt;em&gt;Chairman&lt;/em&gt;) (The Netherlands), Helmut Baumgartner (Germany), Claudio Ceconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (The Netherlands), Paulus Kirchhof (Germany), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril Moulin (France), Bogdan A. Popescu (Romania), Željko Reiner (Croatia), Udo Sechtem (Germany), Per Anton Sirnes (Norway), Michal Tendera (Poland), Adam Torbicki (Poland), Alec Vahanian (France), Stephan Windecker (Switzerland)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Document Reviewers&lt;/em&gt;: Christian Funck-Brentano (&lt;em&gt;CPG Review Coordinator&lt;/em&gt;) (France), Per Anton Sirnes (&lt;em&gt;CPG Review Coordinator&lt;/em&gt;) (Norway), Victor Aboyans (France), Eduardo Alegria Ezquerra (Spain), Colin Baigent (UK), Carlos Brotons (Spain), Gunilla Burell (Sweden), Antonio Ceriello (Spain), Johan De Sutter (Belgium), Jaap Deckers (The Netherlands), Stefano Del Prato (Italy), Hans-Christoph Diener (Germany), Donna Fitzsimons (UK), Zlatko Fras (Slovenia), Rainer Hambrecht (Germany), Piotr Jankowski (Poland), Ulrich Keil (Germany), Mike Kirby (UK), Mogens Lytken Larsen (Denmark), Giuseppe Mancia (Italy), Athanasios J. Manolis (Greece), John McMurray (UK), Andrzej Pająk (Poland), Alexander Parkhomenko (Ukraine), Loukianos Rallidis (Greece), Fausto Rigo (Italy), Evangelista Rocha (Portugal), Luis Miguel Ruilope (Spain), Enno van der Velde (The Netherlands), Diego Vanuzzo (Italy), Margus Viigimaa (Estonia), Massimo Volpe (Italy), Olov Wiklund (Sweden), Christian Wolpert (Germany)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Societies: &lt;sup&gt;1&lt;/sup&gt;European Society of Cardiology (ESC); &lt;sup&gt;2&lt;/sup&gt;European Atherosclerosis Society (EAS); &lt;sup&gt;3&lt;/sup&gt;International Society of Behavioural Medicine (ISBM); &lt;sup&gt;4&lt;/sup&gt;European Stroke Organisation (ESO); &lt;sup&gt;5&lt;/sup&gt;European Society of Hypertension (ESH); &lt;sup&gt;6&lt;/sup&gt;European Association for the Study of Diabetes (EASD); &lt;sup&gt;7&lt;/sup&gt;European Society of General Practice/Family Medicine (ESGP/FM/WONCA); &lt;sup&gt;8&lt;/sup&gt;International Diabetes Federation Europe (IDF-Europe); &lt;sup&gt;9&lt;/sup&gt;European Heart Network (EHN).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Statements from the writing panel disclosing conflicts of interest are available on the European Society of Cardiology (ESC) Web site. Changes in conflicts of interest that arose during the writing period were notified.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The disclosure forms of the authors and reviewers are available on the &lt;a href=&quot;http://www.escardio.org/guidelines&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site.&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="Association of Cardiologists of Bosnia &amp; Herzegovina - Medical Specialty Society" /><FieldValue Value="Belgian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Belorussian Scientific Society of Cardiologists - Medical Specialty Society" /><FieldValue Value="Cardiology Society of Serbia - Medical Specialty Society" /><FieldValue Value="Croatian Cardiac Society - Medical Specialty Society" /><FieldValue Value="Danish Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Estonian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="French Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Hellenic Cardiological Society - Medical Specialty Society" /><FieldValue Value="Hungarian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Israel Heart Society - Medical Specialty Society" /><FieldValue Value="Latvian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Libyan Cardiac Society - Medical Specialty Society" /><FieldValue Value="Lithuanian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Luxembourg Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Polish Cardiac Society - Medical Specialty Society" /><FieldValue Value="Portuguese Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Romanian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="San Marino Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Slovak Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Society of Cardiology of the Russian Federation - Medical Specialty Society" /><FieldValue Value="Spanish Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Turkish Society of Cardiology - Medical Specialty Society" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A, European Society of Cardiology (ESC), European Association for Cardiovascular Prevention and Rehabilitation (EACPR), Council on Cardiovascular Nursing, European Association for Study of Diabetes (EASD), International Diabetes Federation Europe (IDF-Europe), European Stroke Initiative (EUSI), International Society of Behavioural Medicine (ISBM), European Society of Hypertension (ESH), WONCA Europe (European Society of General Practice/Family Medicine), European Heart Network (EHN), European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies [trunc]. Eur J Cardiovasc Prev Rehabil 2007 Sep;(14 Suppl 2):S1-113.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.escardio.org/GUIDELINES-SURVEYS/ESC-GUIDELINES/Pages/cvd-prevention.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;. Also available in &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/TranslatedGuidelinesDocuments/Guidelines-CVD-Prevention-Spanish-2012.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;Spanish&lt;/a&gt; and &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/TranslatedGuidelinesDocuments/Guidelines-%20CVD%20Prev%202012-Turkish.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;Turkish&lt;/a&gt; from the ESC Web site.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK, Tel: +44 (0) 1865 353263, Fax: +44 (0) 1865 353774, Web site: &lt;a href=&quot;http://www.eurheartj.oxfordjournals.org/&quot; title=&quot;European Heart Journal Web site&quot;&gt;http://www.eurheartj.oxfordjournals.org/&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;CVD prevention. Fifth Joint European Societies' Task Force on cardiovascular disease prevention in clinical practice. Essential messages. 2012. 10 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Essential_Messages_CVD_Prevention.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;European guidelines on CVD prevention summary in general practice. 2012. 2 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/GPs_Card_CVD_Prev_.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;European guidelines on CVD prevention in clinical practice. Pocket guidelines. 2012. Electronic copies; Available for order form available from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/products/pocket/Pages/PREV.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;European guidelines on CVD prevention in clinical practice. Slide set. 2012. Electronic copies: Available to registered users from the &lt;a href=&quot;http://www.escardio.org/GUIDELINES-SURVEYS/ESC-GUIDELINES/Pages/cvd-prevention.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;European guidelines on CVD prevention in clinical practice (version 2012). Addenda. 2012. 12 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Guidelines-CVD-Prevention-Addenda.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK, Tel: +44 (0) 1865 353263, Fax: +44 (0) 1865 353774, Web site: &lt;a href=&quot;http://www.eurheartj.oxfordjournals.org/&quot; title=&quot;European Heart Journal Web site&quot;&gt;http://www.eurheartj.oxfordjournals.org/&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additionally, continuing medical education (CME) credit is available online at the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/PREV-CME-questions.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. Relative risk charts (SCORE charts) are available in the &lt;a href=&quot;http://www.escardio.org/GUIDELINES-SURVEYS/ESC-GUIDELINES/Pages/cvd-prevention.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on May 12, 2004. The information was verified by the guideline developer on July 29, 2004. This summary was updated by ECRI Institute on August 27, 2008. This summary was updated by ECRI Institute on January 5, 2010 following the U.S. Food and Drug Administration advisory on Plavix (Clopidogrel). This summary was updated by ECRI Institute on May 17, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs. This summary was updated by ECRI Institute on April 30, 2013. The updated information was verified by the guideline developer on July 3, 2013. This summary was updated by ECRI Institute on April 8, 2015 following the U.S. Food and Drug Administration advisory on Chantix (varenicline).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
